MétaCan
Menu
Back to cohort
Record W4389752263 · doi:10.1111/jne.13359

Use and perceived utility of <scp> [ <sup>18</sup> F]FDG PET/CT </scp> in neuroendocrine neoplasms: A consensus report from the <scp>European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting</scp> 2022

2023· article· en· W4389752263 on OpenAlexaff
Valentina Ambrosini, Martyn Caplin, Justo P. Castaño, Emanuel Christ, Timm Denecke, Christophe M. Deroose, Clarisse Dromain, Massimo Falconi, Simona Grozinsky‐Glasberg, Rodney J. Hicks, Johannes Hofland, Andreas Kjær, Ulrich Knigge, Beata Kos‐Kudła, Anna Koumarianou, B A Rama Krishna, Ángela Lamarca, Marianne Pavel, Nicholas S. Reed, Aldo Scarpa, Rajaventhan Srirajaskanthan, Anders Sundin, Christos Toumpanakis, Vikas Prasad

Bibliographic record

VenueJournal of Neuroendocrinology · 2023
Typearticle
Languageen
FieldMedicine
TopicNeuroendocrine Tumor Research Advances
Canadian institutionsPancreas Centre (Canada)
FundersSirtex MedicalServierEuropean Society for Medical OncologyNovo NordiskEisaiMylanIpsenSociedad Española de Oncología MédicaIncyteNovo Nordisk FondenBoston Scientific CorporationAmgenPfizerAstraZenecaEli Lilly and Company
KeywordsNeuroendocrine tumorsMedicineSomatostatinNeuroendocrine carcinomaInternal medicineRadionuclide therapyBiopsyOncologyNuclear medicineCarcinoma

Abstract

fetched live from OpenAlex

Somatostatin receptor (SST) PET/CT is the gold standard for well-differentiated neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms (NEN) show preferential [18F]FDG (FDG) uptake, and even low-grade NET may de-differentiate over time. FDG PET/CT's prognostic role is widely accepted; however, its impact on clinical decision-making remains controversial and its use varies widely. A questionnaire-based survey on FDG PET/CT use and perceived decision-making utility in NEN was submitted to the ENETS Advisory Board Meeting attendees (November 2022, response rate = 70%). In 3/15 statements, agreement was higher than 75%: (i) FDG was considered useful in NET, irrespective of grade, in case of mis-matched lesions (detectable on diagnostic CT but negative/faintly positive on SST PET/CT), especially if PRRT is contemplated (80%); (ii) in NET G3 if curative surgery is considered (82%); and (iii) in NEC prior to surgery with curative intent (98%). FDG use in NET G3, even in the presence of matched lesions, as a baseline for response assessment was favoured by 74%. Four statements obtained more than 60% consensus: (i) FDG use in NET G3 if locoregional therapy is considered (65%); (ii) in neuroendocrine carcinoma before initiating active therapy as a baseline for response assessment (61%); (iii) biopsy to re-assess tumour grade prior to a change in therapeutic management (68%) upon detection of FDG-positivity on the background of a prior G1-2 NET; (iv) 67% were in favour to reconsider PRRT to treat residual SST-positive lesions after achieving complete remission on FDG of the SST-negative disease component. Multidisciplinary opinion broadly supports the use of FDG PET/CT for characterisation of disease biology and to guide treatment selection across a range of indications, despite the lack of full consensus in many situations. This may reflect existing clinical access due to lack of reimbursement or experience with this investigation, which should be addressed by further research.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.027
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Research integrity
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Case report · Consensus signal: Case report
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.178
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.027
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0010.002
Science and technology studies0.0000.002
Scholarly communication0.0000.001
Open science0.0010.002
Research integrity0.0000.004
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.042
GPT teacher head0.301
Teacher spread0.258 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designCase report
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations21
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of NeuroendocrinologySame topicNeuroendocrine Tumor Research AdvancesFrench-language works237,207